Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Why the Mesoblast (ASX:MSB) share price could soar on FDA news

The Mesoblast Limited (ASX: MSB) share price could soar today on news from the US FDA.

What happened?

Mesoblast said that the United States Food and Drug Administration (FDA) has granted ‘Fast Track’ designation for remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS) due to COVID-19. It recently signed an agreement with Novartis regarding this.

The biotech business explained that fast track designation is granted if a therapy demonstrates the potential to address unmet medical needs for a serious or life-threatening disease. ARDS is the primary cause of death in patients of COVID-19.

Fast track designation by the FDA is intended to facilitate development and expedite the review of therapies to treat serious and life-threatening conditions with no or limited treatment options so that an approved product can reach the market expeditiously. Under this designation, a biological license application (BLA) for remestemcel-L is eligible for both rolling submission and priority review.

One of the things Mesoblast used to support its case was a steady at New York’s Mt Sinai Hospital in March and April this year. In that study, nine of 12 ventilator dependent patients (75%) with moderate to severe COVID-19 ARDS were successfully discharged from a hospital an average of 10 days after receiving two intravenous doses of remestemcel-L.

Mesoblast also updated the market that the ongoing randomised phase 3 trial of remestemcel-L in up to 300 ventilator-dependent patients with moderate to severe COVID-19 ARDS is approximately two-thirds enrolled. This trial’s endpoint is overall mortality at day 30, and the key secondary endpoint is days alive off ventilatory support through day 60. The recommendation by the Data Safety Monitoring Board, is to continue this trial as planned. A third and final interim analysis is planned to be performed by the DSMB when 180 patients have completed 30 days of follow-up.

Summary thoughts

No bad news is good news for Mesoblast. It remains a higher-risk idea because there’s no guarantee that it’s going to be approved. But there is more than one route for Mesoblast to making good shareholder returns from here, it doesn’t need the COVID-19 treatment to be approved – there’s still the original thesis and potential uses for remestemcel-L.

I wouldn’t be surprised to see the Mesoblast share price go up today. But there are other ASX growth shares I’d much rather buy with a simpler path to growth such as Pushpay Holdings Ltd (ASX: PPH).

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content